Brokers Issue Forecasts for Kura Oncology FY2030 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Brookline Capital Management issued their FY2030 earnings per share (EPS) estimates for shares of Kura Oncology in a report issued on Monday, January 5th. Brookline Capital Management analyst L. Cann expects that the company will earn $26.89 per share for the year. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Several other brokerages have also recently commented on KURA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research report on Wednesday, October 8th. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. UBS Group lifted their target price on Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, November 14th. Barclays reiterated an “overweight” rating and issued a $28.00 price target (up from $11.00) on shares of Kura Oncology in a report on Monday, November 24th. Finally, Wedbush reissued an “outperform” rating and set a $38.00 price target (up from $36.00) on shares of Kura Oncology in a research report on Friday, November 14th. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Kura Oncology has an average rating of “Moderate Buy” and an average target price of $26.57.

Kura Oncology Stock Performance

NASDAQ KURA opened at $9.54 on Tuesday. The company has a market capitalization of $830.17 million, a price-to-earnings ratio of -3.85 and a beta of 0.25. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. Kura Oncology has a 12 month low of $5.41 and a 12 month high of $12.49. The company’s fifty day moving average price is $10.76 and its two-hundred day moving average price is $8.73.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The company had revenue of $20.75 million for the quarter, compared to analyst estimates of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.

Hedge Funds Weigh In On Kura Oncology

Several institutional investors have recently modified their holdings of KURA. Vanguard Group Inc. lifted its position in Kura Oncology by 2.2% in the 3rd quarter. Vanguard Group Inc. now owns 5,468,522 shares of the company’s stock valued at $48,396,000 after purchasing an additional 120,197 shares during the last quarter. EcoR1 Capital LLC raised its holdings in shares of Kura Oncology by 59.1% during the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock valued at $24,234,000 after buying an additional 1,559,702 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its position in shares of Kura Oncology by 101.6% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock worth $19,688,000 after buying an additional 1,121,228 shares during the period. Geode Capital Management LLC grew its holdings in Kura Oncology by 11.7% in the 2nd quarter. Geode Capital Management LLC now owns 2,014,029 shares of the company’s stock worth $11,623,000 after buying an additional 211,470 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its holdings in Kura Oncology by 63.0% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after buying an additional 738,761 shares in the last quarter.

Insider Activity at Kura Oncology

In related news, insider Brian T. Powl sold 8,887 shares of the company’s stock in a transaction on Friday, November 14th. The stock was sold at an average price of $11.18, for a total transaction of $99,356.66. Following the completion of the transaction, the insider directly owned 139,689 shares in the company, valued at $1,561,723.02. This represents a 5.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Teresa Brophy Bair sold 8,804 shares of the stock in a transaction on Friday, November 14th. The stock was sold at an average price of $11.18, for a total value of $98,428.72. Following the completion of the sale, the insider directly owned 188,139 shares in the company, valued at $2,103,394.02. This represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 68,343 shares of company stock valued at $730,858. 6.40% of the stock is owned by insiders.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.